These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1204736)

  • 1. Reduction of hypoxia-induced disturbances by previous treatment with benserazide and L-dopa in rats.
    Boismare F; le Poncin M; Belliard JP; Hacpille L
    Experientia; 1975 Oct; 31(10):1190-1. PubMed ID: 1204736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of L-dopa combined with benserazide on hemodynamics and motor activity in hypoxic rats].
    Boismare F; Le Poncin M; Belliard JP; Hacpille L
    C R Seances Soc Biol Fil; 1975; 169(1):203-8. PubMed ID: 126730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Disappearance of the disordered postural regulation of cerebral circulation by the addition of benserazide in parkinsonism treated with L-dopa].
    Boismare F; Samson M; Pouliquen A; Hacpille L
    Therapie; 1976; 31(5):615-22. PubMed ID: 1013953
    [No Abstract]   [Full Text] [Related]  

  • 4. [Improvement with the combination of L-dopa and benserazide of postural dysregulations of the cerebral circulation: preliminary study].
    Boismare F; Boquet J; Lefrançois J; Le Poncin M
    Agressologie; 1977; 18(5):285-6. PubMed ID: 602991
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular responses to acute hypoxia in dogs pretreated with benserazide and L-DOPA.
    Boismare F; Le Poncin M; Hacpille L
    Eur J Pharmacol; 1976 Jul; 38(1):1-5. PubMed ID: 954818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study of the M-H response, of the silent period and of post-tetanic potentiation in subjects with Parkinson's disease during treatment with L-dopa or Madopar].
    Ferro Milone F; Lorizio A; Nordera G
    Riv Neurol; 1975; 45(2):236-46. PubMed ID: 1179114
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: Levodopa and dopadecarboxylase in treatment of postural hypotension.
    Boismare F; Boquet J
    Br Med J; 1975 Mar; 1(5957):573. PubMed ID: 1139159
    [No Abstract]   [Full Text] [Related]  

  • 8. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-dopa and benserazide in the treatment of acute hepatic encephalopathy in infancy.
    Sinniah D; Chan LL
    Singapore Med J; 1980 Aug; 21(4):658-60. PubMed ID: 7221579
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
    Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 14. A histochemical study on the central effect of monoamine precursors.
    Kato N; Murase Y
    Folia Psychiatr Neurol Jpn; 1975; 29(2):189-95. PubMed ID: 1080740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM; Megna GF; Masi G; Specchio LM
    Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
    Hadj Tahar A; Ekesbo A; Grégoire L; Bangassoro E; Svensson KA; Tedroff J; Bédard PJ
    Eur J Pharmacol; 2001 Feb; 412(3):247-54. PubMed ID: 11166288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
    Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE
    Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)].
    Campanella G; Pennetta R
    Riv Patol Nerv Ment; 1974 Oct; 95(5):673-5. PubMed ID: 4470267
    [No Abstract]   [Full Text] [Related]  

  • 19. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 20. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.